Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Insmed Inc’s stock clocked out at $174.84, up 4.98% from its previous closing price of $166.55. In other words, the price has increased by $4.98 from its previous closing price. On the day, 19.05 million shares were traded. INSM stock price reached its highest trading level at $178.21 during the session, while it also had its lowest trading level at $166.7101.
Ratios:
To gain a deeper understanding of INSM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.34 and its Current Ratio is at 4.63. In the meantime, Its Debt-to-Equity ratio is 0.79 whereas as Long-Term Debt/Eq ratio is at 0.77.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 18 ’25 when Lewis William sold 10,699 shares for $166.97 per share. The transaction valued at 1,786,457 led to the insider holds 303,911 shares of the business.
William Lewis bought 10,699 shares of INSM for $1,786,437 on Dec 18 ’25. On Dec 05 ’25, another insider, SHAROKY MELVIN MD, who serves as the Director of the company, sold 20,000 shares for $205.01 each. As a result, the insider received 4,100,200 and left with 243,948 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INSM now has a Market Capitalization of 37288734720 and an Enterprise Value of 36348882944. For the stock, the TTM Price-to-Sale (P/S) ratio is 83.42 while its Price-to-Book (P/B) ratio in mrq is 39.31. Its current Enterprise Value per Revenue stands at 81.313 whereas that against EBITDA is -37.137.
Stock Price History:
The Beta on a monthly basis for INSM is 1.11, which has changed by 1.4768381 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, INSM has reached a high of $212.75, while it has fallen to a 52-week low of $60.40. The 50-Day Moving Average of the stock is -6.43%, while the 200-Day Moving Average is calculated to be 43.70%.
Shares Statistics:
It appears that INSM traded 2.66M shares on average per day over the past three months and 5736420 shares per day over the past ten days. A total of 212.58M shares are outstanding, with a floating share count of 210.36M. Insiders hold about 1.37% of the company’s shares, while institutions hold 100.29% stake in the company. Shares short for INSM as of 1764288000 were 9866791 with a Short Ratio of 3.71, compared to 1761868800 on 8033501. Therefore, it implies a Short% of Shares Outstanding of 9866791 and a Short% of Float of 5.12.
Earnings Estimates
The market rating for Insmed Inc (INSM) is a result of the insights provided by 13.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$1.18, with high estimates of -$0.68 and low estimates of -$1.63.
Analysts are recommending an EPS of between -$4.97 and -$6.92 for the fiscal current year, implying an average EPS of -$6.11. EPS for the following year is -$3.51, with 14.0 analysts recommending between -$1.95 and -$5.36.
Revenue Estimates
In. The current quarter, 16 analysts expect revenue to total $174.27M. It ranges from a high estimate of $197.9M to a low estimate of $154.9M. As of. The current estimate, Insmed Inc’s year-ago sales were $104.44MFor the next quarter, 16 analysts are estimating revenue of $191.71M. There is a high estimate of $208.07M for the next quarter, whereas the lowest estimate is $177.9M.
A total of 18 analysts have provided revenue estimates for INSM’s current fiscal year. The highest revenue estimate was $540.48M, while the lowest revenue estimate was $486.2M, resulting in an average revenue estimate of $517.92M. In the same quarter a year ago, actual revenue was $363.71MBased on 17 analysts’ estimates, the company’s revenue will be $1.22B in the next fiscal year. The high estimate is $1.49B and the low estimate is $1.03B.
